Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Impending Sense Of Regulatory Panic? EU's MDR/IVDR One Year On

Executive Summary

It has been one year since the EU Medical Device and IVD Regulations took effect, leaving two years before the MDR fully applies and four before the IVDR fully applies. What has been achieved? And why is there a sense of panic among some in industry?

You may also be interested in...

ASEAN Medtech Update: Thai Device Law Amended; Vietnam Moots Another Delay; Indonesian Reg System Updated

This month's Asian Medtech Associations' Regulatory Networking discussions focused on amended Thai medical device regulations, more concerns over Vietnam's already-deferred, dedicated medtech legislation, and regulatory news updates from Indonesia. There was also a further take on compliance with the EU MDR, seen from an EU manufacturer's viewpoint. This Asia Networking series is hosted by Medtech Insight and sponsored by the Asia Regulatory and Quality Consultancy (ARQon), and the Asia Regulatory Professionals Association (ARPA).

Who Can Use MDR's Four-Year Derogation Extension? Notified Bodies Try To Clarify

Many companies are pinning hopes on being able to use the EU Medical Device Regulation's four-year extension period for products CE marked under the current directives. But with a lack of clarity from the policymakers so far, TEAM-NB has stepped in.

EU Regulations: The Catastrophic Costs Of Failing To Be A Trailblazer

Whatever the hurdles to compliance with the new EU Medical Device and IVD Regulations, procrastination will cost firms dearly, says Peter Rose, of compliance consulting firm Maetrics. In an interview with Medtech Insight, he stresses the urgency of quick action and calculates the cost to companies that are late to to comply.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts